Skip to main content

Course Details

Released On

March 1, 2026

Expires On

August 31, 2026

Media Type

Internet

Specialties

Education, Hematology & Oncology

Completion Time

30 minutes

Topics

Leukemia, Oncology, Pharmacology

Providers/Grant Support

Provided by Association of Cancer Care Centers.

This activity is supported by an educational grant from Genentech.

Credits Available

All healthcare professionals will receive a certificate of participation for completing the course.

Target Audience

This activity is designed to meet the educational needs of members of the multidisciplinary CLL care team: Oncologists/heme oncologists, oncology APPs (NPs, pharmacists, PAs), oncology nurses, oncology navigators, oncology clinical social workers, and other members of the cancer care team who are involved with care for patients with CLL.

Program Overview

This activity will highlight new treatment options for CLL, best practices, shared decision-making, and incorporating patient preferences into treatment decisions.

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  1. Discuss new therapeutic options (with an emphasis on oral/oral combination therapies), including treatment initiation and management, lab monitoring, patient logistics, and how these new options may impact the patient experience
  2. Help providers garner a better understanding of patient preferences around fixed duration vs. treat-to-progression regimens
  3. Review best practices in shared decision making (SDM) around fixed duration vs. treat-to-progression and key issues to be discussed in the SDM process (eg, patient preferences, costs, travel/transportation)
  4. Discuss the benefits of being off CLL treatment when receiving covid vaccines (share data showing this potentially leads to stronger immune response/antibody formation/immune protection)

Faculty

Helou 135

Christine Helou, MSN, FNP-BC, OCN

Oncology Nurse Practitioner
Virginia Cancer Specialists
Fairfax, VA

Sandoval 135

Jose Sandoval Sus, MD, FACP

Hematologic Oncologist, Associate Member
Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System
Pembroke Pines, FL

Kittai 135

Adam Kittai, MD

Associate Professor of Medicine
Assistant Director of Lymphoma Clinical Research
Mount Sinai
New York, NY

Sharman 135

Jeff Sharman, MD

Medical Oncologist, Hematologist
Willamette Valley Cancer Institute
Eugene, OR

Instructions for Participation and Credit

There are no fees for participating in this enduring activity. To receive certification of completion participants must:

  1. Participate in the online activity.
  2. Submit the evaluation form.

Certificates will be available for the participant to download. 

Course Viewing Requirements

Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome 

Supported Phones & Tablets:
All devices

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: [email protected]